B
rain-specific expression of a therapeutic gene requires the use of (i) organ-specific promoter elements and (ii) a transcellular targeting system that enables delivery of the transgene across both the blood-brain barrier (BBB) and the brain cell plasma membrane. Prior work has demonstrated the widespread expression of exogenous genes in the brain of rats after the i.v. injection of pegylated immunoliposomes (PILs) that carry the plasmid DNA in the interior of the nanocontainer (1). The PIL͞DNA was targeted to brain cells with a peptidomimetic mAb to the rat transferrin receptor (TfR). Owing to the abundance of the TfR on the brain capillary endothelium, which forms the BBB in vivo, the mAb targeted the exogenous gene to brain cells in vivo in the rat (1) . However, the TfR is also abundant in some peripheral tissues, such as liver and spleen, and the exogenous gene, driven by the simian virus 40 (SV40) promoter, also was expressed in liver and spleen after the i.v. injection of the PIL (2) .
The present studies test the hypothesis that the expression of an exogenous gene can be restricted to the brain with the use of both the PIL gene targeting technology and a brain-specific promoter. The expression in brain and peripheral organs is measured for either a luciferase or a ␤-galactosidase exogenous gene. The plasmid DNA encapsulated in the 8D3-PIL is administered i.v., and the exogenous gene is under the influence of either the SV40 promoter or the human glial fibrillary acidic protein (GFAP) promoter (3, 4) . A second goal of this work was to develop a gene targeting system specific for the mouse, given the availability of transgenic mouse models of human disease. Prior work in rats used the mouse OX26 mAb to the rat TfR (1, 2) , but the OX26 mAb is not active in mice (5) . The rat 8D3 mAb to the mouse TfR is an active BBB transport vector in mice (5) , and the present studies describe the production of PILs targeted with the 8D3 mAb.
The structure of the PIL gene targeting system is shown in Fig.  1A , and this formulation is to be contrasted with conventional cationic lipid͞DNA complexes. The PIL has a net negative charge (2) and internalizes the DNA in the interior of the liposome to render the plasmid DNA resistant to the endogenous endonucleases, which are ubiquitous in vivo (6) . Any exteriorized DNA is removed from the PIL formulation by nuclease treatment and gel filtration chromatography (1, 2) . The liposome surface is decorated with 2,000-3,000 strands of 2,000-Da polyethylene glycol, designated PEG 2000 . The ''pegylation'' of the liposome prevents absorption of serum proteins to the surface of the structure and minimizes uptake of the liposome by cells lining the reticuloendothelial system (7). The pegylated liposome is directed to tissues in vivo by tethering to the tips of 1-2% of the PEG strands a targeting peptidomimetic mAb (Fig. 1 A) . The anti-TfR mAb binds to the BBB TfR to trigger receptor-mediated transcytosis across the BBB in vivo, and this process is followed by Tfr-mediated endocytosis of the PIL into brain cells (1, 2) .
Experimental Procedures
Materials. Adult male BALB͞c mice (25-30 g) were purchased from Harlan Breeders, Indianapolis. dCTP (specific activity: 800 Ci͞mmol) was from Perkin-Elmer. N-succinimidyl [2, H] propionate (specific activity: 97.0 Ci͞mmol) was supplied by Amersham Pharmacia. DNase I, exonuclease III, and the Nick Translation Kit were from GIBCO͞BRL. Traut's reagent was purchased from Pierce. Lipids for liposome synthesis were supplied by Avanti Polar Lipids. The LiposoFAST-Basic extruder and polycarbonate filters were from Avestin, Ottawa. 5-Bromo-4-chloro-3-indoyl-␤-D-galactoside, rat IgG, and all other chemicals were purchased from Sigma. The pSV-␤-galactosidase expression plasmid driven by the SV40 promoter, the pGL3-control luciferase expression plasmid driven by the SV40 promoter, the luciferase reagent, and recombinant luciferase were obtained from Promega. The pGfa-lacZ ␤-galactosidase expression plasmid was provided by Jose Segovia, Centro de Investigacìon y de Estudios Avanzados, San Pedro Zacatenco, Mexico (3, 4) . In this plasmid, the lacZ gene is driven by the human GFAP promoter (nucleotides Ϫ2163 to ϩ47). The GFAP ATG at position ϩ15 was mutated to TTG, so translation Abbreviations: BBB, blood-brain barrier; GFAP, glial fibrillary acidic protein; PIL, pegylated immunoliposome; PEG, polyethylene glycol; TfR, transferrin receptor; HIR, human insulin receptor; SV40, simian virus 40.
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begins at the lacZ ATG initiation codon. The 3Ј untranslated region (UTR) following the lacZ gene is derived from the mouse protamine gene-1 3Ј UTR, and contains an intron and poly(A) sequence (3, 4) . The orientation of the GFAP promoter within the plasmid was confirmed by DNA sequencing. The 8D3 hybridoma line, secreting a rat IgG to the mouse Tfr (8), was obtained from Britta Engelhardt, Max Planck Institute, Bad Naoheim, Germany.
Plasmid DNA Preparation and Radiolabeling. ␤-Galactosidase or luciferase plasmid DNA was purified from Escherichia coli with the maxiprep procedure and desalted by using the Qiagen (Chatsworth, CA) Plasmid Maxi Kit and QIAquick PCR purification kit, respectively. The size of the DNA was confirmed by 0.8% agarose gel electrophoresis. DNA was labeled with 32 PdCTP using nick translation. The specific activity of 32 P-DNA was 15-20 Ci͞g. The purity measured by trichloroacetic acid precipitability was 99%.
mAb Purification and Radiolabeling. The rat 8D3 anti-mouse TfR mAb was purified with protein G Sepharose affinity chromatography from ascites generated in nude mice. All animal procedures were performed with protocols approved by the University of California Los Angeles Animal Research Committee. The 8D3 hybridoma was grown on a feeder layer of newborn mouse thymocytes and peritoneal cells, as described by Kissel et al. (8) . The antibody was tritiated with N-succinimidyl[2,3-3 H] propionate as described (9) . The specific activity and trichloroacetic acid precipitability of the 3 H-8D3 mAb were 100-150 Ci͞mg and 95%, respectively. PIL Synthesis. PILs were synthesized by using a total of 20 mmol of lipids, including 18.8 mmol of 1-palmitoyl-2-oleoyl-snglycerol-3-phosphocholine (POPC), 0.4 mmol of didodecyldimethylammonium bromide (DDAB), 0.6 mmol of distearoylphosphatidylethanolamine (DSPE-PEG), and 200 nmol of DSPE-PEG-maleimide, as described (1, 2). The supercoiled plasmid DNA (150 g) and 2 Ci of 32 P-plasmid DNA were encapsulated in the pegylated liposomes, and exteriorized DNA was degraded by nuclease digestion, as described (1, 2). The thiolated 8D3 mAb was conjugated to the pegylated liposome overnight at room temperature. The 8D3 PIL͞DNA was separated from degraded DNA absorbed to the exterior of the liposome, and from unconjugated mAb, using a 1.6 ϫ 18 cm column of Sepharose CL-4B (Fig. 1B) . The average number of 8D3 mAbs conjugated on one liposome was 50 and was computed from the measurement of radioactive mAb, as described (10) . The DNA encapsulation efficiency was 20%. The control rat IgG PIL͞␤-galactosidase plasmid DNA was prepared by following the same procedure.
In Vivo Administration and Gene Expression Assays. Male BALB͞c mice weighing 25-30 g were anesthetized with ketamine (50 mg͞kg) and xylazine (4 mg͞kg) i.p. PIL conjugated with either the 8D3 mAb or nonspecific rat IgG, and carrying either the pSV-␤-galactosidase plasmid DNA, the pGfa-lacZ plasmid DNA, or the pGL3-control plasmid DNA was injected i.v. in mice via the jugular or femoral vein with a 30-g needle at a dose of 3-5 g of PIL-encapsulated plasmid DNA per mouse. Mice were killed at 24, 48, and 72 h postinjection. Brain, liver, spleen, kidney, heart, and lung were removed and frozen in OCT embedding medium for ␤-galactosidase histochemistry, or homogenized in 4 vol of lysis buffer for measurements of organ luciferase activity, as described (1). For histochemistry, frozen sections of 18-m thickness were fixed in 0.1% glutaraldehyde in 0.1 M NaH 2 PO 4 for 5 min and incubated with 0.1% 5-bromo-4-chloro-3-indoyl-␤-D-galactoside at pH ϭ 7.0 at 37°C overnight, as described (1, 2). Whole-mount images of the organs were obtained by scanning the section with a UMAX PowerLookIII scanner with transparency adapter, and the image was cropped in Adobe PHOTOSHOP 5.5 on a G4 Power Macintosh computer. The luciferase enzyme activity was measured in organ supernatants with a Luminometer (Biolumat LB 9507, Berthold, Nashua, NH), as described (1) . A standard curve was assayed in parallel with recombinant luciferase, and the relative light units were converted to pg of luciferase. The protein concentration in the tissue extract was determined with the BCA protein assay reagent (Pierce), and the luciferase activity in the organ was expressed as pg luciferase͞mg protein.
Confocal Microscopy. Mouse brain frozen sections (20 m) were fixed with 100% acetone at Ϫ20°C for 20 min. The sections were incubated in primary antibody for 1 h at room temperature. The primary antibodies were mixed and included a goat antihuman͞rodent GFAP 1:20 polyclonal antiserum (Research Diagnostics, Chicago), and a mouse mAb against E. coli ␤-galactosidase, 20 g͞ml (Promega). After a PBS wash, a rhodamine-conjugated donkey anti-goat IgG 1:200 (Research Diagnostics) secondary antibody was added for 30 min at room temperature. The slides were then washed and incubated with fluorescein-conjugated goat anti-mouse IgG (Sigma) for 30 min at room temperature. The sections were mounted on slides with Vector Shield (Vector Laboratories) mounting media, and viewed with a ϫ10 or ϫ100 objective and a Zeiss LSM 5 PASCAL confocal microscope with dual argon and heli- 
Results
The organ luciferase activity at 48 and 72 h after a single i.v. injection of the pGL3 plasmid DNA encapsulated in the 8D3-PIL is shown in Table 1 and indicates the 8D3 mAb targets the gene to TfR-rich organs such as brain, liver, spleen, and lung, with very little gene expression in kidney or heart. The results with the 8D3 TfR mAb in the mouse replicate previous work with the OX26 TfR mAb in the rat (1) .
Administration of the pSV-␤-galactosidase plasmid encapsulated in the 8D3-PIL resulted in gene expression in both brain and peripheral tissues, such as spleen (Fig. 2A) . The pGfa-lacZ plasmid also was encapsulated in 8D3-PIL and injected i.v. in mice, and organs were removed 2 days later for ␤-galactosidase histochemistry (Fig. 2B) . Whereas the GFAP͞␤-galactosidase gene was widely expressed throughout the mouse brain, there was no expression of the transgene in mouse spleen, liver, heart, or lung (Fig. 2B) . Gene targeting of organs in vivo was determined by the specificity of the targeting mAb. When the 8D3 rat mAb to the murine TfR was replaced with nonspecific rat IgG (rIgG), and the GFAP͞␤-galactosidase plasmid was encapsulated in the interior of the rIgG-PIL, there was no gene expression in brain or peripheral tissues (lung, spleen, liver, or heart) (Fig. 2C) . Owing to high expression of endogenous mammalian ␤-galactosidase in mouse kidney, this organ serves as a positive control for the histochemical assay (Fig. 2C) . The ␤-galactosidase activity in mouse kidney represents endogenous mammalian enzyme, and this activity does not arise from expression of the bacterial ␤-galactosidase gene in kidney.
The extent to which the exogenous gene is expressed throughout the central nervous system is demonstrated with serial coronal sections through the septo-striatum, the rostral dien- cephalon, the rostral mesencephalon, and the caudal mesencephalon (Fig. 3A) . Gene expression is detected widely throughout the cortical and subcortical structures at all levels of brain. In the septo-striatum, the GFAP͞␤-galactosidase gene is expressed in the caudate putamen nucleus and the epithelium of the choroid plexus lining the lateral ventricles and the third ventricle. At the level of the rostral diencephalon, there is gene expression in the parietal cortex, the hippocampus, and the thalamic nuclei (Fig. 3A) . In the caudal mesencephalon, gene expression is observed throughout the cerebellum and the posterior colliculus anteriorly and various hindbrain nuclear structures posteriorly. The expression in mouse brain of the GFAP͞␤-galactosidase gene peaks at 48 h after a single i.v. injection as shown in Fig. 3B . Temporal studies were performed with a SV40͞␤-galactosidase plasmid, which showed a reduced gene expression at 24 h compared with the GFAP͞␤-galactosidase and a level of ␤-galactosidase gene expression in the brain at 72 h that was comparable to the activity at 48 h in Fig. 2 A. Confocal microscopy confirmed the expression of the ␤-galactosidase transgene in astrocytes (Fig. 4) . The expression of immunoreactive ␤-galactosidase and immunoreactive GFAP in the same brain cell is shown in Fig. 4 A and B , respectively, and the yellow signal in the superimposed image demonstrates immune labeling of both the cell body and the processes of the astrocyte (Fig. 4C) . Astrocyte foot processes invest the basement membrane surface of the cerebral microvasculature, and these structures express immunoreactive GFAP, as shown in Fig. 4 E and H. Immunoreactive bacterial ␤-galactosidase is also expressed in the astrocyte foot processes investing the microvasculature as shown in Fig. 4 D and G . The orange͞yellow signal in the superimposed image demonstrates colocalization of the GFAP and the bacterial ␤-galactosidase in the astrocyte processes (Fig. 4 F and I) .
Discussion
These studies are consistent with the following conclusions. First, exogenous genes encoding for either luciferase or ␤-galactosidase and under the influence of the SV40 promoter are targeted to brain in the mouse using PILs and the rat 8D3 mAb to the mouse TfR. However, the transgene is also targeted to TfR-rich peripheral tissues such as spleen, liver, and lung (Table  1 , Fig. 2 A) . Second, the expression of the exogenous gene in peripheral organs can be eliminated when the exogenous gene is under the influence of a brain-specific promoter, such as the 2 kb of the 5Ј flanking sequence of the human GFAP gene (Fig.  2B) . Third, the PIL gene targeting technology enables the widespread expression throughout the central nervous system of an exogenous gene after the noninvasive i.v. administration of a nonviral formulation of the gene (Fig. 3A) . Fourth, the expression of the exogenous gene in brain persists for at least 3 days after the single i.v. administration (Table 1, Fig. 3B) . Fifth, the ␤-galactosidase transgene, under the influence of the GFAP promoter, is widely expressed in both cell bodies and processes of astrocytes, as demonstrated by confocal microscopy (Fig. 4) .
The 8D3-PIL delivers the exogenous gene both to brain and TfR-rich peripheral tissues (Table 1) . However, when the transgene is under the inf luence of a brain-specific promoter, there is no gene expression in peripheral tissues (Fig. 2B) . The absence of measurable expression of the transgene in lung (Fig. 2B) contrasts the PIL gene targeting system with conventional cationic lipid͞DNA complexes. After the i.v. injection of cationic liposome͞DNA complexes, the level of gene expression in the lung is log orders greater than in peripheral tissues such as liver or spleen, and there is no gene expression in brain (11) . The absence of significant gene expression in liver (Fig. 2B) contrasts the PIL system with the adenovirus gene delivery system, wherein Ͼ90% of the exogenous gene is expressed in mouse liver after the i.v. administration of adenoviral vector systems (12) .
Transgene expression peaks at 2 days after a single i.v. injection and starts to decline by 3 days, when the gene is driven by a GFAP promoter (Fig. 3B) . The SV40 promoter gives a greater persistence of the transgene in both mice (Table 1) and rats (2) . The level of gene expression does not decline to the 50% level until 6 days after i.v. administration of the SV40͞␤-galactosidase in rats, as measured by either histochemistry or Southern blotting (2) . The persistence of a therapeutic gene may be increased with the use of expression plasmids that contain gene elements that enable extra-chromosomal replication of the plasmid DNA (13) . In addition to persistence of gene expression, a goal of gene targeting is the organ specificity, and even cellular specificity, of transgene expression. This degree of specificity is possible with the use of organ-or cell-specific promoter elements.
The expression in the mouse of the ␤-galactosidase gene was restricted to the brain, if the ␤-galactosidase gene was under the influence of the GFAP promoter (Fig. 2B) . The pattern of ␤-galactosidase brain histochemistry shown in Fig. 3 for adult mice administered the transgene i.v. is similar to the ␤-galactosidase histochemistry of the brain of transgenic mice expressing the ␤-galactosidase gene under the influence of the human GFAP promoter (3) . The expression of the ␤-galactosidase transgene in astrocytes was confirmed in the present studies with confocal microscopy (Fig. 4) . Three-dimensional reconstruction of the confocal images of peri-vascular astrocytes reveals the rosette-like structures that invest the basement membrane surface of the brain capillary (Fig. 4 E and H) , and these structures express the bacterial ␤-galactosidase (Fig. 4 D and G) . These rosette-like structures of the astrocyte foot processes are identical to those in normal rat brain, as described by Kacem et al. (14) . The ␤-galactosidase transgene also is expressed in the cell bodies of astrocytes as shown in Fig. 4 A-C .
In summary, brain-specific expression of an exogenous gene is possible with the combined use of a brain-specific promoter and a gene targeting system using PILs. This gene delivery system offers the same advantages of viral delivery systems, such as (i) interiorization of the exogenous gene in a nanocontainer, and protection from ubiquitous endonucleases in vivo, and (ii) surface proteins that trigger uptake of the gene by target cells. 
